Bromo-DragonFLY

Bromo-DragonFLY is a psychoactive drug that is related to the phenethylamine family. It is known for its complex and long-lasting effects, which can last for up to several days. Bromo-DragonFLY is considered a research chemical, meaning it is not approved for medical use and is often used in scientific research.

History

Bromo-DragonFLY was first synthesized in 1998 by the team of David E. Nichols at Purdue University. It was originally developed as a tool for neuroscience research, specifically for studying the 5-HT2A receptor. The drug's effects were first documented in the scientific literature in 2001.

Pharmacology

Bromo-DragonFLY is a potent agonist for the 5-HT2A receptor, which is involved in the regulation of mood, anxiety, and perception. It also has affinity for other serotonin receptors, including 5-HT1A, 5-HT1B, and 5-HT1D. The drug's effects are thought to be primarily due to its action on these receptors.

Effects

The effects of Bromo-DragonFLY are highly variable and can last for up to several days. They can include hallucinations, altered perception of time, and intense emotional experiences. Some users have also reported physical effects such as increased heart rate, high blood pressure, and vasoconstriction.

Legal status

The legal status of Bromo-DragonFLY varies by country. In some countries, it is classified as a controlled substance, while in others it is legal to possess and use.

See also

• Phenethylamine
• Psychedelic drug
• Research chemical

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia